The first indication that VCP inhibitors could be useful against lymphoma was a study by Wang et al., which showed that EER-1 has a strongly preferential cytotoxic activity against several human haematological cancer cell lines (including mantle cell and Burkitt’s lymphoma lines) relative to blood mononuclear cells [15]. Here, VCP is linked to Burkitt lymphoma.